Delivery Order SPE2DB24D1104-SPE2DB25FYFB1
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,455.79 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin product used in diabetes treatment and represents part of the agency's ongoing...
- The Defense Logistics Agency awarded a delivery order valued at $1,248.90 to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL). This is a firm fixed price delivery order with no set-aside designation, utilizing competitive procurement procedures. The order is scheduled for completion by July 21, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin product...
- The Defense Logistics Agency awarded a $2,145.94 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of NovoLog 100 Unit/ML vials (10 ML units). This is a firm fixed-price, non-set-aside contract with a completion date of August 11, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin product used in diabetes management and represents a critical pharmaceutical commodity within the...
- The Defense Logistics Agency awarded a $9,344.14 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) with an ultimate completion date of August 13, 2025. This firm fixed-price contract was competitively awarded with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin used in diabetes management, representing part of the broader pharmaceutical supply chain...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of NovoLog 100 unit/mL vials (10 mL) with a ceiling value of $3,162.88. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The order is due for completion by July 30, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin used in diabetes...
- The Defense Logistics Agency awarded a delivery order valued at $4,819.02 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL). The contract, classified as a firm fixed price delivery order with an ultimate completion date of August 18, 2025, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL) with a ceiling value of $1,424.55. This competitive award, issued under a firm fixed-price delivery order contract type, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The order does not utilize a...
- The Defense Logistics Agency awarded a delivery order valued at $2,765.03 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vial 10mL insulin medication on August 21, 2025, with completion scheduled for August 22, 2025. This competitive award, issued under firm fixed pricing terms, represents a routine pharmaceutical supply transaction supporting military healthcare operations. The award was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $2,737.35 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of NovoLog 100 Unit/mL vials (10mL). The contract, which is a child order under a larger indefinite delivery contract, carries an ultimate completion date of August 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a non-competitive, competitively awarded transaction...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,696.30 for NovoLog 100 Unit/ML vials (10 mL) on August 8, 2025, with an ultimate completion date of August 11, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal medical...
- SPE2DB24D1104Indefinite Delivery Contract
- SPE2DB24D1104-SPE2DB25FYFB1Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,155.66 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) on August 27, 2025, with completion scheduled for August 28, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin used in diabetes management, representing a critical pharmaceutical supply for military and federal healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen Drug Corp serves as a prime vendor supplying a comprehensive range of medications, vaccines, and medical supplies to support military healthcare programs globally. The company's federal contract portfolio demonstrates its capability to fulfill diverse medical procurement requirements across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 8/27/25 |